采用放射免疫测定法对６０例肺癌患者、６０例良性肺部疾患患者进行β２－微球蛋白（β２－ＭＧ）、血清分泌型ＩｇＡ（ＳＩｇＡ）、铁蛋白（ＳＦ）和癌胚抗原（ＣＥＡ）含量的血清学联合检测。结果显示：肺癌组此四项血清肿瘤标志物均高于良性肺部疾患组及对照组，其阳性率分别为６６．７％、７０．０％、５３．５％和６０．０％，而６０例肺癌组中无一例出现四项检测均阴性者。因此，β２－ＭＧ、ＳＩｇＡ、ＳＦ和ＣＥＡ含量的测定均可作为诊断肺癌的辅助指标，且不同肿瘤标志物联合检测可明显提高肺癌检出率。 Β2-MG, SIgA, SF and CEA in 60 patients with lung cancer and 60 patients with benign lung disease were measured by radioimmunoassay. Serum content of the joint detection. The results showed that the four serum tumor markers in lung cancer group were higher than those in benign lung disease group and control group, and the positive rates were 66.7%, 70.0%, 53.5% and 60.0%, respectively None of the 60 lung cancer cases had any of the four tests negative. Therefore, the determination of β2-MG, SIgA, SF and CEA levels can be used as an auxiliary indicator of lung cancer diagnosis, and the combination of different tumor markers can significantly increase the detection rate of lung cancer.